A
13.92
0.00 (0.00%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Aardvark Therapeutics, Inc. | 看涨 | - |
AIStockmoo 评分
1.0
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.00 |
|
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 14.22% |
| 机构持股比例 | 49.49% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Silverarc Capital Management, Llc | 31 Mar 2025 | 119,496 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (HC Wainwright & Co., 187.36%) | 购买 |
| 中 | 30.00 (115.52%) | |
| 低 | 20.00 (RBC Capital, 43.68%) | 购买 |
| 平均值 | 30.00 (115.52%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 11.31 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Jun 2025 | 40.00 (187.36%) | 购买 | 13.52 |
| RBC Capital | 15 May 2025 | 20.00 (43.68%) | 购买 | 9.09 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合